Skip to content
drillr.ai
Sign up

SCYX

SCYNEXIS INC

NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US

$3.66
−0.27%
Ask drillr

  • Oct 6, 2026, 11:30 UTC

    SCYNEXIS announced Phase 1 study results for SCY-770, a novel oral direct AMPK activator for the treatment of autosomal dominant polycystic kidney disease (ADPKD), reporting it was well tolerated with a favorable safety profile in healthy adult participants.

    Source:

  • Sep 28, 2026, 20:17 UTC

    SCYNEXIS Inc signed a contract with the Biomedical Advanced Research and Development Authority (BARDA) worth up to $214 million to develop SCY-247, with an initial base period of approximately $18.5 million for a Phase 2 study.

  • Sep 28, 2026, 11:30 UTC

    SCYNEXIS was awarded a contract by BARDA worth up to $214 million in non-dilutive funding to advance development of its second-generation antifungal candidate SCY-247.

    Source:

  • Sep 22, 2026, 12:11 UTC

    SCYNEXIS Inc. appointed Steven K. Burke, M.D. to its Board of Directors effective September 18, 2026, with compensation including an annual retainer of $45,000 and equity grants.

  • Sep 10, 2026, 12:12 UTC

    SCYNEXIS Inc. appointed Sanjay Subramanian as Chief Financial Officer effective September 9, 2026.

    Source:

  • Sep 10, 2026, 12:12 UTC

    SCYNEXIS Inc. Chief Financial Officer Ivor Macleod retired effective September 9, 2026.

  • Aug 25, 2026, 23:06 UTC

    SCYNEXIS, Inc. granted an inducement equity award to a new Senior Director in connection with the commencement of employment, approved under Nasdaq Listing Rule 5635(c)(4).

    Source:

  • Jun 30, 2026, 12:00 UTC

    SCYNEXIS initiated a Phase 1 study of SCY-770, a novel AMPK activator for ADPKD.

    Source: